Alopexx, Inc. (ALPX)

Alopexx will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet

Company Description

Alopexx is a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal, and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG).

To date over 75 separate pathogens have been found to express PNAG. While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management’s assessment that the broad-spectrum potential of our therapeutics will allow them to be used for the prevention, treatment, and mitigation of a wide range of infections.

In a first-in-man trial, our vaccine candidate, AV0328, has been shown to be well tolerated with no serious adverse events observed. It was noted to induce protective antibodies against all PNAG-expressing pathogens tested.

We believe our vaccine’s broad-spectrum potential will allow it to be used for the long-term prevention of a wide range of infections including pneumococcal pneumonia, methicillin-resistant Staphylococcus aureus (MRSA), meningitis, and sexually transmitted diseases.

Similarly, our fully human monoclonal antibody, F598, that also targets PNAG, has been shown to be well tolerated and no serious adverse events were noted in phase 1 and pilot phase 2 trials.

We believe it can provide immediate protection lasting 2-3 months. We seek to establish F598 as the standard of care for preventing and ameliorating gram-negative and gram-positive bacterial infections along with fungal infections by organisms that express PNAG in patients admitted to intensive care units (ICU).

Utilization of these therapeutics also has potential applicability beyond infectious diseases, including treatment of neurological conditions and cognitive decline due to inflammation.

Alopexx, Inc.
Country United States
Founded 2006
Industry Health Care
Sector Biotechnology
CEO Daniel R. Vlock

Contact Details

Address:
186 Alewife Brook Pkwy #1068
Cambridge, MA 02138
United States
Phone (617) 780-1598
Website alopexx.com

Stock Details

Ticker Symbol ALPX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
CIK Code 1880995

Key Executives

Name Position
Daniel R Vlock, MD President, Chief Executive Officer and Director
Thomas T. Thomas Chief Financial Officer
Gerald B. Pier, PhD Chief Scientific Officer
William W. Chin, MD Senior Strategic Advisor, Director
Christine de los Reyes, PharmD, MBA Chief Business Officer, Chief Commercialization Officer
Peter J. Werth Director

Latest SEC Filings

Date Type Title
May 31, 2022 S-1/A General form for registration of securities under the Securities Act of 1933
May 2, 2022 S-1/A General form for registration of securities under the Securities Act of 1933
Apr 20, 2022 S-1/A General form for registration of securities under the Securities Act of 1933
Apr 7, 2022 S-1/A General form for registration of securities under the Securities Act of 1933
Mar 4, 2022 S-1 General form for registration of securities under the Securities Act of 1933
Jan 7, 2022 DRS Draft Registration Statement